XML 61 R47.htm IDEA: XBRL DOCUMENT v3.20.4

Revenues - Disaggregation of Revenues (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disaggregation of Revenue [Line Items]
Product revenues									$ 24,689	$ 22,449	$ 22,127
Total revenues	$ 7,421	$ 6,577	$ 5,143	$ 5,548	$ 5,879	$ 5,604	$ 5,685	$ 5,281	24,689	22,449	22,127
U.S.
Disaggregation of Revenue [Line Items]
Total revenues									18,217	16,645	16,269
Europe
Disaggregation of Revenue [Line Items]
Total revenues									4,135	3,811	4,006
Other International
Disaggregation of Revenue [Line Items]
Total revenues									2,337	1,993	1,852
Product sales
Disaggregation of Revenue [Line Items]
Product revenues									24,355	22,119	21,677
Product sales | U.S.
Disaggregation of Revenue [Line Items]
Product revenues									18,141	16,565	16,197
Product sales | Europe
Disaggregation of Revenue [Line Items]
Product revenues									3,894	3,567	3,696
Product sales | Other International
Disaggregation of Revenue [Line Items]
Product revenues									2,320	1,987	1,784
Total HIV product sales
Disaggregation of Revenue [Line Items]
Product revenues									16,938	16,438	14,627
Total HIV product sales | U.S.
Disaggregation of Revenue [Line Items]
Product revenues									13,651	13,315	11,654
Total HIV product sales | Europe
Disaggregation of Revenue [Line Items]
Product revenues									2,287	2,312	2,350
Total HIV product sales | Other International
Disaggregation of Revenue [Line Items]
Product revenues									1,000	811	623
HIV Products, Atripla
Disaggregation of Revenue [Line Items]
Product revenues									349	600	1,206
HIV Products, Atripla | U.S.
Disaggregation of Revenue [Line Items]
Product revenues									307	501	967
HIV Products, Atripla | Europe
Disaggregation of Revenue [Line Items]
Product revenues									21	60	131
HIV Products, Atripla | Other International
Disaggregation of Revenue [Line Items]
Product revenues									21	39	108
HIV Products, Biktarvy
Disaggregation of Revenue [Line Items]
Product revenues									7,259	4,738	1,184
HIV Products, Biktarvy | U.S.
Disaggregation of Revenue [Line Items]
Product revenues									6,095	4,225	1,144
HIV Products, Biktarvy | Europe
Disaggregation of Revenue [Line Items]
Product revenues									735	370	39
HIV Products, Biktarvy | Other International
Disaggregation of Revenue [Line Items]
Product revenues									429	143	1
HIV Products, Complera/Eviplera
Disaggregation of Revenue [Line Items]
Product revenues									269	406	653
HIV Products, Complera/Eviplera | U.S.
Disaggregation of Revenue [Line Items]
Product revenues									89	160	276
HIV Products, Complera/Eviplera | Europe
Disaggregation of Revenue [Line Items]
Product revenues									159	214	327
HIV Products, Complera/Eviplera | Other International
Disaggregation of Revenue [Line Items]
Product revenues									21	32	50
HIV Products, Descovy
Disaggregation of Revenue [Line Items]
Product revenues									1,861	1,500	1,581
HIV Products, Descovy | U.S.
Disaggregation of Revenue [Line Items]
Product revenues									1,526	1,078	1,217
HIV Products, Descovy | Europe
Disaggregation of Revenue [Line Items]
Product revenues									197	255	308
HIV Products, Descovy | Other International
Disaggregation of Revenue [Line Items]
Product revenues									138	167	56
HIV Products, Genvoya
Disaggregation of Revenue [Line Items]
Product revenues									3,338	3,931	4,624
HIV Products, Genvoya | U.S.
Disaggregation of Revenue [Line Items]
Product revenues									2,605	2,984	3,631
HIV Products, Genvoya | Europe
Disaggregation of Revenue [Line Items]
Product revenues									490	664	794
HIV Products, Genvoya | Other International
Disaggregation of Revenue [Line Items]
Product revenues									243	283	199
HIV Products, Odefsey
Disaggregation of Revenue [Line Items]
Product revenues									1,672	1,655	1,598
HIV Products, Odefsey | U.S.
Disaggregation of Revenue [Line Items]
Product revenues									1,172	1,180	1,242
HIV Products, Odefsey | Europe
Disaggregation of Revenue [Line Items]
Product revenues									450	438	335
HIV Products, Odefsey | Other International
Disaggregation of Revenue [Line Items]
Product revenues									50	37	21
HIV Products, Stribild
Disaggregation of Revenue [Line Items]
Product revenues									196	369	644
HIV Products, Stribild | U.S.
Disaggregation of Revenue [Line Items]
Product revenues									125	268	505
HIV Products, Stribild | Europe
Disaggregation of Revenue [Line Items]
Product revenues									54	75	97
HIV Products, Stribild | Other International
Disaggregation of Revenue [Line Items]
Product revenues									17	26	42
HIV Products, Truvada
Disaggregation of Revenue [Line Items]
Product revenues									1,448	2,813	2,997
HIV Products, Truvada | U.S.
Disaggregation of Revenue [Line Items]
Product revenues									1,376	2,640	2,605
HIV Products, Truvada | Europe
Disaggregation of Revenue [Line Items]
Product revenues									27	101	260
HIV Products, Truvada | Other International
Disaggregation of Revenue [Line Items]
Product revenues									45	72	132
Other HIV
Disaggregation of Revenue [Line Items]
Product revenues									58	47	61
Other HIV | U.S.
Disaggregation of Revenue [Line Items]
Product revenues									25	30	40
Other HIV | Europe
Disaggregation of Revenue [Line Items]
Product revenues									5	5	7
Other HIV | Other International
Disaggregation of Revenue [Line Items]
Product revenues									28	12	14
Revenue share - Symtuza
Disaggregation of Revenue [Line Items]
Product revenues									488	379	79
Revenue share - Symtuza | U.S.
Disaggregation of Revenue [Line Items]
Product revenues									331	249	27
Revenue share - Symtuza | Europe
Disaggregation of Revenue [Line Items]
Product revenues									149	130	52
Revenue share - Symtuza | Other International
Disaggregation of Revenue [Line Items]
Product revenues									8	0	0
Total HCV product sales
Disaggregation of Revenue [Line Items]
Product revenues									2,064	2,936	3,686
Total HCV product sales | U.S.
Disaggregation of Revenue [Line Items]
Product revenues									1,088	1,465	2,023
Total HCV product sales | Europe
Disaggregation of Revenue [Line Items]
Product revenues									414	742	896
Total HCV product sales | Other International
Disaggregation of Revenue [Line Items]
Product revenues									562	729	767
Ledipasvir/Sofosbuvir
Disaggregation of Revenue [Line Items]
Product revenues									272	643	1,222
Ledipasvir/Sofosbuvir | U.S.
Disaggregation of Revenue [Line Items]
Product revenues									92	312	802
Ledipasvir/Sofosbuvir | Europe
Disaggregation of Revenue [Line Items]
Product revenues									29	71	144
Ledipasvir/Sofosbuvir | Other International
Disaggregation of Revenue [Line Items]
Product revenues									151	260	276
Sofosbuvir/Velpatasvir
Disaggregation of Revenue [Line Items]
Product revenues									1,599	1,965	1,966
Sofosbuvir/Velpatasvir | U.S.
Disaggregation of Revenue [Line Items]
Product revenues									864	971	934
Sofosbuvir/Velpatasvir | Europe
Disaggregation of Revenue [Line Items]
Product revenues									337	553	654
Sofosbuvir/Velpatasvir | Other International
Disaggregation of Revenue [Line Items]
Product revenues									398	441	378
Other HCV
Disaggregation of Revenue [Line Items]
Product revenues									193	328	498
Other HCV | U.S.
Disaggregation of Revenue [Line Items]
Product revenues									132	182	287
Other HCV | Europe
Disaggregation of Revenue [Line Items]
Product revenues									48	118	98
Other HCV | Other International
Disaggregation of Revenue [Line Items]
Product revenues									13	28	113
Veklury
Disaggregation of Revenue [Line Items]
Product revenues									2,811	0	0
Veklury | U.S.
Disaggregation of Revenue [Line Items]
Product revenues									2,026	0	0
Veklury | Europe
Disaggregation of Revenue [Line Items]
Product revenues									607	0	0
Veklury | Other International
Disaggregation of Revenue [Line Items]
Product revenues									178	0	0
Total Cell Therapy product sales
Disaggregation of Revenue [Line Items]
Product revenues									607	456	264
Total Cell Therapy product sales | U.S.
Disaggregation of Revenue [Line Items]
Product revenues									396	373	263
Total Cell Therapy product sales | Europe
Disaggregation of Revenue [Line Items]
Product revenues									201	83	1
Total Cell Therapy product sales | Other International
Disaggregation of Revenue [Line Items]
Product revenues									10	0	0
Cell Therapy Products, Yescarta
Disaggregation of Revenue [Line Items]
Product revenues									563	456	264
Cell Therapy Products, Yescarta | U.S.
Disaggregation of Revenue [Line Items]
Product revenues									362	373	263
Cell Therapy Products, Yescarta | Europe
Disaggregation of Revenue [Line Items]
Product revenues									191	83	1
Cell Therapy Products, Yescarta | Other International
Disaggregation of Revenue [Line Items]
Product revenues									10	0	0
Call Therapy Products, Tecartus
Disaggregation of Revenue [Line Items]
Product revenues									44	0	0
Call Therapy Products, Tecartus | U.S.
Disaggregation of Revenue [Line Items]
Product revenues									34	0	0
Call Therapy Products, Tecartus | Europe
Disaggregation of Revenue [Line Items]
Product revenues									10	0	0
Call Therapy Products, Tecartus | Other International
Disaggregation of Revenue [Line Items]
Product revenues									0	0	0
Trodelvy
Disaggregation of Revenue [Line Items]
Product revenues									49	0	0
Trodelvy | U.S.
Disaggregation of Revenue [Line Items]
Product revenues									49	0	0
Trodelvy | Europe
Disaggregation of Revenue [Line Items]
Product revenues									0	0	0
Trodelvy | Other International
Disaggregation of Revenue [Line Items]
Product revenues									0	0	0
Total Other product sales
Disaggregation of Revenue [Line Items]
Product revenues									1,886	2,289	3,100
Total Other product sales | U.S.
Disaggregation of Revenue [Line Items]
Product revenues									931	1,412	2,257
Total Other product sales | Europe
Disaggregation of Revenue [Line Items]
Product revenues									385	430	449
Total Other product sales | Other International
Disaggregation of Revenue [Line Items]
Product revenues									570	447	394
Other Products, AmBisome
Disaggregation of Revenue [Line Items]
Product revenues									436	407	420
Other Products, AmBisome | U.S.
Disaggregation of Revenue [Line Items]
Product revenues									61	37	46
Other Products, AmBisome | Europe
Disaggregation of Revenue [Line Items]
Product revenues									230	234	229
Other Products, AmBisome | Other International
Disaggregation of Revenue [Line Items]
Product revenues									145	136	145
Letairis
Disaggregation of Revenue [Line Items]
Product revenues										618	943
Letairis | U.S.
Disaggregation of Revenue [Line Items]
Product revenues									314	618	943
Letairis | Europe
Disaggregation of Revenue [Line Items]
Product revenues									0	0	0
Letairis | Other International
Disaggregation of Revenue [Line Items]
Product revenues									0	0	0
Ranexa
Disaggregation of Revenue [Line Items]
Product revenues										216	758
Ranexa | U.S.
Disaggregation of Revenue [Line Items]
Product revenues									9	216	758
Ranexa | Europe
Disaggregation of Revenue [Line Items]
Product revenues									0	0	0
Ranexa | Other International
Disaggregation of Revenue [Line Items]
Product revenues									0	0	0
Other Products, Vemlidy
Disaggregation of Revenue [Line Items]
Product revenues									657	488	321
Other Products, Vemlidy | U.S.
Disaggregation of Revenue [Line Items]
Product revenues									356	309	245
Other Products, Vemlidy | Europe
Disaggregation of Revenue [Line Items]
Product revenues									29	21	12
Other Products, Vemlidy | Other International
Disaggregation of Revenue [Line Items]
Product revenues									272	158	64
Other Products, Viread
Disaggregation of Revenue [Line Items]
Product revenues									185	243	307
Other Products, Viread | U.S.
Disaggregation of Revenue [Line Items]
Product revenues									14	32	50
Other Products, Viread | Europe
Disaggregation of Revenue [Line Items]
Product revenues									34	69	82
Other Products, Viread | Other International
Disaggregation of Revenue [Line Items]
Product revenues									137	142	175
Other Products, Zydelig
Disaggregation of Revenue [Line Items]
Product revenues									72	103	133
Other Products, Zydelig | U.S.
Disaggregation of Revenue [Line Items]
Product revenues									31	47	61
Other Products, Zydelig | Europe
Disaggregation of Revenue [Line Items]
Product revenues									39	54	70
Other Products, Zydelig | Other International
Disaggregation of Revenue [Line Items]
Product revenues									2	2	2
Other
Disaggregation of Revenue [Line Items]
Product revenues									213	214	218
Other | U.S.
Disaggregation of Revenue [Line Items]
Product revenues									146	153	154
Other | Europe
Disaggregation of Revenue [Line Items]
Product revenues									53	52	56
Other | Other International
Disaggregation of Revenue [Line Items]
Product revenues									14	9	8
Royalty, contract and other revenues
Disaggregation of Revenue [Line Items]
Product revenues									334	330	450
Total revenues									334	330	450
Royalty, contract and other revenues | U.S.
Disaggregation of Revenue [Line Items]
Total revenues									76	80	72
Royalty, contract and other revenues | Europe
Disaggregation of Revenue [Line Items]
Total revenues									241	244	310
Royalty, contract and other revenues | Other International
Disaggregation of Revenue [Line Items]
Total revenues									$ 17	$ 6	$ 68

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	srt_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=gild_OtherInternationalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_HIVProductSalesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_HIVProductsAtriplaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_HIVProductsStribildMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_HCVProductSalesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_OtherHCVMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_COVID19ProductsVekluryMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_OtherProductsYescartaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_CallTherapyProductsTecartusMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_COVID19ProductsTrodelvyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_OtherProductsRanexaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_OtherProductsVemlidyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_OtherProductsVireadMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_OtherProductsZydeligMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_OtherProductsOtherMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: